PLASMA IDOL, SOLUBLE LDLR AND PCSK9 LEVELS AS POTENTIAL BIOMARKERS OF FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN

被引：0
|
作者：
Girona, J. [1 ]
Rodriguez-Borjabad, C. [2 ]
Ibarretxe, D. [2 ]
Heras, M. [1 ]
Amigo, N. [3 ]
Feliu, A. [4 ]
Masana, L. [1 ,2 ]
Plana, N. [2 ]
机构：
[1] URV, CIBERDEM, IISPV, Res Unit Lipids & Atherosclerosis, Reus, Spain
[2] URV, St Joan Univ Hosp, CIBERDEM, IISPV,Vasc Med & Metab Unit, Reus, Spain
[3] URV, CIBERDEM, IISPV, Biosfer Teslab, Reus, Spain
[4] Univ Rovira & Virgili, IISPV, Pediat Res Unit, Reus, Spain
来源：
ATHEROSCLEROSIS | 2018年 / 275卷
关键词：
D O I：
10.1016/j.atherosclerosis.2018.06.051
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAG3.3
引用
收藏
页码：E22 / E22
页数：1
相关论文
共 50 条
  • [41] LDLR and PCSK9 3′ UTR variants and their putative effects on microRNA molecular interactions in familial hypercholesterolemia: a computational approach
    de Freitas, Renata Caroline Costa
    Bortolin, Raul Hernandes
    Borges, Jessica Bassani
    de Oliveira, Victor Fernandes
    Dagli-Hernandez, Carolina
    Marcal, Elisangela da Silva Rodrigues
    Bastos, Gisele Medeiros
    Goncalves, Rodrigo Marques
    Faludi, Andre Arpad
    Silbiger, Vivian Nogueira
    Luchessi, Andre Ducati
    Hirata, Rosario Dominguez Crespo
    Hirata, Mario Hiroyuki
    MOLECULAR BIOLOGY REPORTS, 2023, 50 (11) : 9165 - 9177
  • [42] No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia
    Schol-Gelok, Suzanne
    Galema-Boers, J. M. H.
    van Gelder, Teun
    Kruip, Marieke J. H. A.
    van Lennep, Jeanine E. Roeters
    Versmissen, Jorie
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 108 : 1412 - 1414
  • [43] The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype
    Drouin-Chartier, Jean-Philippe
    Tremblay, Andre J.
    Hogue, Jean-Charles
    Ooi, Teik C.
    Lamarche, Benoit
    Couture, Patrick
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2015, 64 (11): : 1541 - 1547
  • [44] PCSK9 analysis in familial hypercholesterolaemia patients negative for LDLR and APOB mutations
    George, P. M.
    Homer, V. M.
    Laurie, A. D.
    Hurndell, N.
    Scott, R. S.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 135 - 135
  • [45] THE ROLE OF CAP1 IN PCSK9 REGULATION OF LDLR LEVELS
    Seidah, Nabil
    Gaillard, Carole Fruchart
    Ouadda, Ali Ben Djoudi
    HEPATOLOGY, 2021, 74 : 295A - 295A
  • [46] PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies
    El Khoury, Petra
    Elbitar, Sandy
    Ghaleb, Youmna
    Abou Khalil, Yara
    Varret, Mathilde
    Boileau, Catherine
    Abifadel, Marianne
    CURRENT ATHEROSCLEROSIS REPORTS, 2017, 19 (12)
  • [47] PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies
    Petra El Khoury
    Sandy Elbitar
    Youmna Ghaleb
    Yara Abou Khalil
    Mathilde Varret
    Catherine Boileau
    Marianne Abifadel
    Current Atherosclerosis Reports, 2017, 19
  • [48] A Decision Aid for the Use of PCSK9 Inhibitors in Patients With Familial Hypercholesterolemia
    Farwati, Medhat
    Shaw, Kevin
    Hargraves, Ian G.
    Montori, Victor M.
    Kullo, Iftikhar J.
    CIRCULATION, 2018, 138
  • [49] PCSK9 Inhibitors for Homozygous Familial Hypercholesterolemia Useful But Seldom Sufficient
    Thompson, Gilbert R.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (02) : 143 - 145
  • [50] LIPOPROTEIN(A) IN FAMILIAL HYPERCHOLESTEROLEMIA WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
    Tada, Hayato
    Kawashiri, Masa-Aki
    Nohara, Atsushi
    Inazu, Akihiro
    Mabuchi, Hiroshi
    Yamagishi, Masakazu
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 1896 - 1896
12345